Synapse - Steven Horwitz

Search Within

Steven M Horwitz

Results (671)

Final results of phase II trial of doxorubicin HCI liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma

Journal Article

Straus, D. J.; Duvic, M.; Horwitz, S. M.; Hymes, K.; Goy, A.; Hernandez-Ilizaliturri, F. J.; Feldman, T.; Wegner, B.; Myskowski, P. L.
Annals of Oncology (2014)

Fulltext@MSK | Save

Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): Part II. Prognosis, management, and future directions

Journal Article

Jawed, S. I.; Myskowski, P. L.; Horwitz, S.; Moskowitz, A.; Querfeld, C.
Journal of the American Academy of Dermatology (2014)

Fulltext@MSK | Save

Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): Part I. Diagnosis: Clinical and histopathologic features and new molecular and biologic markers

Journal Article

Jawed, S. I.; Myskowski, P. L.; Horwitz, S.; Moskowitz, A.; Querfeld, C.
Journal of the American Academy of Dermatology (2014)

Fulltext@MSK | Save

Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: Pivotal study update demonstrates durable responses

Journal Article

Coiffier, B.; Pro, B.; Prince, H. M.; Foss, F.; Sokol, L.; Greenwood, M.; Caballero, D.; Morschhauser, F.; Wilhelm, M.; Pinter-Brown, L.; more...
Journal of Hematology & Oncology (2014)

Fulltext@MSK | Save

Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-δ,γ, in patients with relapsed/refractory CLL

Meeting Abstract

Patel, M. R.; Kahl, B. S.; Horwitz, S. M.; Younes, A.; Foss, F. M.; Oki, Y.; Sweeney, J.; Allen, K.; Faia, K.; Kelly, P. F.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): Results from the BELIEF trial

Meeting Abstract

O'Connor, O. A.; Masszi, T.; Savage, K. J.; Pinter-Brown, L. C.; Foss, F. M.; Popplewell, L.; Cashen, A. F.; Doorduijn, J.; Chawla, S.; Knoblauch, P.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-δ,γ in patients with relapsed/refractory lymphoma

Meeting Abstract

Horwitz, S. M.; Flinn, I.; Patel, M. R.; Younes, A.; Foss, F. M.; Oki, Y.; Sweeney, J.; Allen, K.; Dunbar, J.; Kelly, P. F.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Brentuximab vedotin administered before, during, and after multi-agent chemotherapy in patients (pts) with newly-diagnosed CD30+ mature T- and NK-cell lymphomas

Meeting Abstract

Fanale, M. A.; Horwitz, S. M.; Forero-Torres, A.; Bartlett, N. L.; Advani, R. H.; Pro, B.; Chen, R.; Davies, A.; Illidge, T.; Huebner, D.; more...
Blood (2013)

Fulltext@MSK | Save

Analysis of peripheral T-cell lymphoma (PTCL) subtype by race and geography using the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) dataset

Meeting Abstract

Carson, K. R.; Foss, F. M.; Pinter-Brown, L.; Horwitz, S. M.; Rosen, S. T.; Pro, B.; Federico, M.; Gisselbrecht, C.; Hsi, E. D.
Blood (2013)

Fulltext@MSK | Save

Romidepsin is effective and well-tolerated in patients >= 60 years old with relapsed or refractory peripheral T-cell lymphoma (PTCL): Analysis from phase 2 trials

Meeting Abstract

Shustov, A. R.; Coiffier, B.; Horwitz, S. M.; Sokol, L.; Pro, B.; Nielsen, T.; Wolfson, J.; Balser, B. E.; Eisch, R.; Popplewell, L.; more...
Blood (2013)

Fulltext@MSK | Save